Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Vir Biotechnology's profit margin for the twelve months ending Sep 30, 2026 was -61.0%. For fiscal 2025 it was -638.9%, against -703.4% the year before. The highest annual figure on record is 48.3% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -638.9% | +64.5 |
| FY2024 | Dec 31, 2024 | -703.4% | +10.3 |
| FY2023 | Dec 31, 2023 | -713.7% | −745.6 |
| FY2022 | Dec 31, 2022 | 31.9% | −16.3 |
| FY2021 | Dec 31, 2021 | 48.3% | +439.3 |
| FY2020 | Dec 31, 2020 | -391.1% | +1767.9 |
| FY2019 | Dec 31, 2019 | -2159.0% | −1072.7 |
| FY2018 | Dec 31, 2018 | -1086.3% | +1493.2 |
| FY2017 | Dec 31, 2017 | -2579.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 33.5% | +4023.1 |
| Q4 FY2025 | Dec 31, 2025 | -67.0% | +778.2 |
| Q3 FY2025 | Sep 30, 2025 | -67975.4% | −58995.7 |
| Q2 FY2025 | Jun 30, 2025 | -9139.9% | −4639.8 |
| Q1 FY2025 | Mar 31, 2025 | -3989.6% | −3873.8 |
| Q4 FY2024 | Dec 31, 2024 | -845.2% | −154.4 |
| Q3 FY2024 | Sep 30, 2024 | -8979.7% | −2787.5 |
| Q2 FY2024 | Jun 30, 2024 | -4500.1% | +629.6 |
| Q1 FY2024 | Mar 31, 2024 | -115.8% | +108.1 |
| Q4 FY2023 | Dec 31, 2023 | -690.9% | −485.2 |
| Q3 FY2023 | Sep 30, 2023 | -6192.2% | −6239.0 |
| Q2 FY2023 | Jun 30, 2023 | -5129.7% | −5171.8 |
| Q1 FY2023 | Mar 31, 2023 | -223.9% | −288.5 |
| Q4 FY2022 | Dec 31, 2022 | -205.6% | −312.2 |
| Q3 FY2022 | Sep 30, 2022 | 46.8% | +11.9 |
| Q1 FY2022 | Mar 31, 2022 | 42.1% | +8590.2 |
| Q4 FY2021 | Dec 31, 2021 | 64.6% | +6157.4 |
| Q3 FY2021 | Sep 30, 2021 | 106.6% | +4495.0 |
| Q2 FY2021 | Jun 30, 2021 | 34.9% | +81.4 |
| Q1 FY2021 | Mar 31, 2021 | -8548.1% | −7197.3 |
| Q4 FY2020 | Dec 31, 2020 | -6092.8% | +414.5 |
| Q3 FY2020 | Sep 30, 2020 | -4388.4% | −944.8 |
| Q2 FY2020 | Jun 30, 2020 | -46.5% | +1610.9 |
| Q1 FY2020 | Mar 31, 2020 | -1350.8% | −567.7 |
| Q4 FY2019 | Dec 31, 2019 | -6507.2% | −5662.9 |
| Q3 FY2019 | Sep 30, 2019 | -3443.6% | −2284.0 |
| Q2 FY2019 | Jun 30, 2019 | -1657.4% | −558.3 |
| Q1 FY2019 | Mar 31, 2019 | -783.1% | +515.2 |
| Q4 FY2018 | Dec 31, 2018 | -844.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -1159.7% | – |
| Q2 FY2018 | Jun 30, 2018 | -1099.2% | – |
| Q1 FY2018 | Mar 31, 2018 | -1298.4% | – |
See a number that looks wrong?